Vitruvias Therapeutics and Sinotherapeutics team up to launch bioequivalent Rythmol SR in US
Vitruvias Therapeutics, a US-based finished-dose generic drug manufacturer, has announced the US launch of a bioequivalent, FDA-approved version of the antiarrhythmic drug Rythmol SR, in collaboration with the Chinese pharmaceutical company Sinotherapeutics. The product, known generically as propafenone hydrochloride, is being introduced as an extended-release version of the original Rythmol SR. Rythmol SR is an […]